Skip to content

Hypertension in chronic kidney disease patients on hemodialysis

Randomized control trial to compare effect of Atenolol vs Telmisartan in hemodialysis patients with uncontrolled hypertension.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052911
Enrollment
152
Registered
2023-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Atenolol: Patients on hemodialysis with uncontrolled blood pressure will be given atenolol 25 mg three times a week and dose will be gradually increased to 100mg three times a week till

Sponsors

Department of Nephrology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the end stage kidney disease patients, above 18 years of age with written informed consent. - On Hemodialysis (CKD stage VD) for more than 3 months. Average of Home BP readings should be more than 135/85mmHg. These readings should be collected in the morning and in the evening over 6 non-dialysis days (covering a period of 2 weeks). OR - ABPM reading with an average BP of more than 130/80mmHg over 24-h monitoring during a mid-week day free of haemodialysis.

Exclusion criteria

Exclusion criteria: 1. Patients less than 18 yrs of age. 2. Patient with pregnancy. 3. Patients with obstructive airway disease, peripheral vascular disease, uncontrolled blood sugar levels. 4. Patients with persistent hyperkalemia [K > 6meq/L], or with ECG changes of hyperkalemia 5. Patients planned to undergo renal transplant within 1 year. 6. Patients with CV events in the last 3 months 7. Patients unwilling to give consent.

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME Decrease in Echocardiographic Left Ventricular hypertrophy and Left Ventricular Mass Index at the end of 1 year Timepoint: 12 months

Secondary

MeasureTime frame
SECONDARY OUTCOME Composite Cardiovascular outcome at the end of one year which include heart failure,coronary revascularization (PTCA/ CABG), myocardial ischemia, angina requiring hospitalization, hemorrhagic and non hemorrhagic intracranial infarcts and intracranial bleeding. Improvement in ABPM parameter- Average systolic and diastolic BP, Night to day Systolic BP ratio at the end of 1 year. Adverse effects seen the usage of drugs- hyperkalemia, bradycardia, hypotension (less than 100mmHG systolic BP), arrythmia during 1 year. Secondary arterio venous fistula failure due to hypotension during 1 year Number of anti hypertensive medications required for control of blood pressure at 1 year Number of hospitalization due to cardiac failure during 1 year Hospitalization due to uncontrolled blood pressure within 1 year All cause mortality in 1 year. Timepoint: 1 year

Countries

India

Contacts

Public ContactDr Sreyashi Bose

Seth GSMC and KEM hospital Mumbai

tukaramjamale@yahoo.co.in09167460362

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026